Novozymes’ tunable half-life extension (HLE) technology can flexibly extend half-life to reduce the dosing frequency of drugs from days to weeks. Based on albumin, Novozymes offers HLE by genetic fusion – Albufuse Flex, or chemical conjugation – Recombumin Flex, enabling the tunability of HLE to meet the needs of a specific disease or application.
Leading the way in improving patient quality of life, Novozymes’ technology is already being widely used in the fields of diabetes, haemophilia and neutropenia.
Through the optimisation of drug half-life, dosing frequency and healthcare costs can be reduced while increasing patient compliance. Long patents until at least 2030 also provide manufacturers with a unique competitive edge in current challenging markets.
For further information on Novozymes’ HLE technology, please visit www.halflifeextension.com.
Hall 9 Stand B56
